Use of human immunodeficiency virus (HIV) type 1 and 2 recombinant strip immunoblot assay to resolve enzyme immunoassay anti-HIV-2-repeatably reactive samples after anti-HIV-1/2 combination enzyme immunoassay screening.

@article{Tobler1997UseOH,
  title={Use of human immunodeficiency virus (HIV) type 1 and 2 recombinant strip immunoblot assay to resolve enzyme immunoassay anti-HIV-2-repeatably reactive samples after anti-HIV-1/2 combination enzyme immunoassay screening.},
  author={Leslie H. H. Tobler and Ezra Kaufman and N Gefter and C D Schable and Michael P. Busch},
  journal={Transfusion},
  year={1997},
  volume={37 9},
  pages={921-5}
}
BACKGROUND With the implementation of combination human immunodeficiency virus types 1 and 2 (HIV-1/2) antibody enzyme immunoassay (EIA) in donor screening in 1992, the supplemental testing algorithm changed to require the use of a Food and Drug Administration (FDA)-licensed HIV-1 Western blot (WB) or immunofluorescence assay, as well as an FDA-licensed HIV-2 EIA. When HIV-2 EIA-reactive specimens are identified, further testing to confirm HIV-2 infection is recommended. Currently, a licensed… CONTINUE READING